ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

isoquercitrin

Also written as “Kinisoquin™” and “Isoquercetin”.

Its studies are mostly in Venous Thromboembolism · COVID-19, led by 2 companies.

Drug pageIsoquercitrin: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 9, 20202 company-led studies, 1 open or runningNext primary completion: Oct 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AB Science10 open or runningphase 2since Nov 9, 2020Nov 9, 2020none ahead
Quercis Pharmaits history only11 open or runningphase 3since Feb 28, 2025Feb 28, 2025Oct 31, 2027phase 3 · NCT06861088

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AB Science only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2020First study: phase 2 study in COVID-19First studyNCT04622865 · 200 enrolled · France

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study AB Science leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04622865COVID-19 · France2UNKNOWNDec 2023200

How it is read

Names in the registry

  • “Kinisoquin™”, 1 entry
  • “Isoquercetin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.